business
Senators Advance Bill to Cap Insulin at $35 for Private Insurance and Uninsured
U.S. senators are reviving a proposal to extend the $35 insulin price cap beyond Medicare to the private market and uninsured patients. The measure is modeled on a 2022 law that already limits costs for Medicare beneficiaries.
Audio version
Tap play to generate a narrated version.
Developing·Limited corroboration so far. This page will refresh as more sources emerge.
Senators are advancing legislation that would cap the price of insulin at $35 per month for people with private insurance and those without coverage. The bill follows a similar provision that Democrats added to a 2022 tax-and-health care law applying only to Medicare. Sponsors say the new measure would broaden access to the same price limit.
Background on the Proposal The effort is led by Sen.
Susan Collins (R-Maine), who added two more co-sponsors last week. She faces reelection this fall. The proposal is part of a wider push by lawmakers to highlight affordability measures ahead of the campaign season.
Separately, the head of a Swiss pharmaceutical industry trade group said the U.S. could open a Section 301 trade investigation into Switzerland similar to one already underway against Germany. Washington began that probe after Germany announced plans in April to overhaul its statutory health care system and lower spending on medicines.
The investigation could lead to tariff action on German imports. Switzerland is also reviewing steps to reduce mandatory health care prices, a move the industry has criticized.
